MARKET

ORGS

ORGS

Orgenesis Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.860
-0.040
-0.82%
After Hours: 4.860 0 0.00% 16:00 11/25 EST
OPEN
4.830
PREV CLOSE
4.900
HIGH
4.980
LOW
4.700
VOLUME
17.06K
TURNOVER
--
52 WEEK HIGH
8.20
52 WEEK LOW
2.350
MARKET CAP
117.40M
P/E (TTM)
-1.9730
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
No Data
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ORGS. Analyze the recent business situations of Orgenesis Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ORGS stock price target is 9.00 with a high estimate of 9.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 53
Institutional Holdings: 6.12M
% Owned: 25.32%
Shares Outstanding: 24.16M
TypeInstitutionsShares
Increased
11
237.32K
New
12
-48.90K
Decreased
13
320.95K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.74%
Pharmaceuticals & Medical Research
+0.82%
Key Executives
Chairman/Chief Executive Officer/Director
Vered Caplan
Chief Financial Officer/Treasurer/Secretary
Neil Reithinger
Corporate Executive
Denis Bedoret
Corporate Executive
Darren Head
Chief Scientific Officer
Sarah Ferber
Independent Director
Yaron Adler
Independent Director
Ashish Nanda
Independent Director
Mario Philips
Independent Director
David Sidransky
Independent Director
Guy Yachin
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ORGS
Orgenesis Inc. is a biopharmaceutical company. The Company is developing, manufacturing and processing of technologies and services in the cell and gene therapy industry. The Company operates a point-of-care (POCare) cell therapy platform (POC). The POC platform develops Advanced Therapy Medicinal Products (ATMPs) through collaborations and in-licensing with other pre-clinical and clinical-stage biopharmaceutical companies and research and healthcare institutes to bring such ATMPs to patient. The POC platform include a multitude of cell therapies, including autoimmune, oncologic, neurologic and metabolic diseases and other indications.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Orgenesis Inc stock information, including NASDAQ:ORGS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORGS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ORGS stock methods without spending real money on the virtual paper trading platform.